🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHeart failure hospitalization reduction on semaglutide — 6 month update Page 3

Heart failure hospitalization reduction on semaglutide — 6 month update

ricardo_MIA Thu, Feb 22, 2024 at 4:53 AM 17 replies 2,290 viewsPage 3 of 4
Dr.LipidDallas
VIP Member
2,678
14,567
Dec 2023
Dallas, TX
Feb 25, 2024 at 11:10 AM#11
CarlaRPh_TPA said:
The mechanism that matters here is not stomach emptying, it is central.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

Last edited: Feb 25, 2024 at 1:10 PM
45 18pam_stl, wei_SG, cory_ATX and 42 others
Reply Quote Save Share Report
tommy_boulder
Member
234
1,123
Nov 2024
Boulder, CO
Feb 25, 2024 at 8:05 PM#12
emma_london said:
All true, with one condition: that curve is for people who reached the dose on schedule.

Saving this. It is the first explanation that did not require me to already understand it. I will report back once I have actually tried it.

46 19TinaHashiRN, robert_kc, dan_philly and 43 others
Reply Quote Save Share Report
Dr.SurgeonPGH
Senior Member
1,345
6,789
Mar 2024
Pittsburgh, PA
Feb 26, 2024 at 4:59 AM#13
CarlaRPh_TPA said:
The mechanism that matters here is not stomach emptying, it is central.

This is where I part company with the consensus forming above. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

47 20PharmHunterJen, TomTeleRx, DoseLogDan and 44 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
Feb 26, 2024 at 1:53 PM#14
ricardo_MIA said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -2.3 lbs/week average
Fasting glucose (finger stick): stable at 86 mg/dL
Blood pressure (home): 118/72 average
Resting heart rate: 66 bpm (down from 82)
Waist circumference: down 16 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.

48 21hans_munich, jason_sac26, chris_chi24 and 45 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Feb 26, 2024 at 10:47 PM#15

Moderator note: a couple of off-topic posts removed. Report rather than reply if it drifts again.

49 22PurityPaulOR, MaxMetOK, MounjBrad and 46 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register